Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $5.77.

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research report on Tuesday, January 7th.

CytomX Therapeutics Trading Down 3.6 %

NASDAQ:CTMX opened at $0.80 on Friday. CytomX Therapeutics has a 1 year low of $0.75 and a 1 year high of $5.85. The stock has a 50-day moving average price of $0.97 and a two-hundred day moving average price of $1.08. The stock has a market cap of $62.32 million, a price-to-earnings ratio of 4.68 and a beta of 1.01.

Institutional Investors Weigh In On CytomX Therapeutics

Several institutional investors have recently bought and sold shares of CTMX. Miller Financial Services LLC acquired a new stake in shares of CytomX Therapeutics in the fourth quarter valued at approximately $26,000. Traphagen Investment Advisors LLC bought a new position in CytomX Therapeutics in the fourth quarter valued at $31,000. US Bancorp DE acquired a new stake in CytomX Therapeutics in the 3rd quarter valued at $40,000. Prudential Financial Inc. lifted its position in CytomX Therapeutics by 76.2% during the 4th quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company’s stock worth $66,000 after buying an additional 27,800 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of CytomX Therapeutics by 96.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 40,309 shares in the last quarter. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.